HBM9161 Injection (680mg)
Sponsors
Harbour BioMed (Guangzhou) Co. Ltd.
Conditions
Myasthenia Gravis
Phase 3
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
CompletedNCT05039190
Start: 2021-09-25End: 2023-01-14Updated: 2023-03-08
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
CompletedNCT05332210
Start: 2022-06-30End: 2024-04-26Updated: 2026-04-28